[go: up one dir, main page]

MA39347B2 - Protéines de fusion d'uti - Google Patents

Protéines de fusion d'uti

Info

Publication number
MA39347B2
MA39347B2 MA39347A MA39347A MA39347B2 MA 39347 B2 MA39347 B2 MA 39347B2 MA 39347 A MA39347 A MA 39347A MA 39347 A MA39347 A MA 39347A MA 39347 B2 MA39347 B2 MA 39347B2
Authority
MA
Morocco
Prior art keywords
fusion proteins
uti fusion
uti
proteins
producing
Prior art date
Application number
MA39347A
Other languages
English (en)
Other versions
MA39347A1 (fr
Inventor
Aaron Chamberlain
Qiang Liu
Mathias Schmidt
Original Assignee
Takeda Pharmaceuticals Co
Takeda Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co, Takeda Gmbh filed Critical Takeda Pharmaceuticals Co
Publication of MA39347A1 publication Critical patent/MA39347A1/fr
Publication of MA39347B2 publication Critical patent/MA39347B2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des protéines de fusion d'uti, des séquences d'adn pour produire ces protéines, et des compositions pharmaceutiques et des méthodes d'utilisation correspondantes.
MA39347A 2014-02-24 2015-02-23 Protéines de fusion d'uti MA39347B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461943617P 2014-02-24 2014-02-24
PCT/US2015/017152 WO2015127391A1 (fr) 2014-02-24 2015-02-23 Protéines de fusion d'uti

Publications (2)

Publication Number Publication Date
MA39347A1 MA39347A1 (fr) 2018-06-29
MA39347B2 true MA39347B2 (fr) 2020-05-29

Family

ID=52629709

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39347A MA39347B2 (fr) 2014-02-24 2015-02-23 Protéines de fusion d'uti

Country Status (38)

Country Link
US (4) US9856310B2 (fr)
EP (2) EP3443978A1 (fr)
JP (4) JP6574431B2 (fr)
KR (3) KR102461210B1 (fr)
CN (2) CN110092837B (fr)
AR (1) AR101597A1 (fr)
AU (4) AU2015218704B2 (fr)
BR (1) BR112016019390B1 (fr)
CA (2) CA3178241A1 (fr)
CL (1) CL2016002136A1 (fr)
CR (1) CR20160444A (fr)
CY (1) CY1120997T1 (fr)
DK (1) DK3110434T3 (fr)
DO (1) DOP2016000202A (fr)
EA (2) EA202091567A1 (fr)
EC (1) ECSP16076535A (fr)
ES (1) ES2700149T3 (fr)
GE (2) GEAP201814277A (fr)
HR (1) HRP20182029T1 (fr)
IL (1) IL247321B (fr)
JO (1) JO3729B1 (fr)
LT (1) LT3110434T (fr)
MA (1) MA39347B2 (fr)
MX (4) MX2016010950A (fr)
MY (1) MY178774A (fr)
NZ (3) NZ760789A (fr)
PE (1) PE20170257A1 (fr)
PH (1) PH12016501629B1 (fr)
PL (1) PL3110434T3 (fr)
PT (1) PT3110434T (fr)
RS (1) RS58285B1 (fr)
SG (2) SG10201708400QA (fr)
SI (1) SI3110434T1 (fr)
SM (1) SMT201800674T1 (fr)
TW (1) TWI694084B (fr)
UA (1) UA118866C2 (fr)
WO (1) WO2015127391A1 (fr)
ZA (1) ZA201606327B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA39347B2 (fr) * 2014-02-24 2020-05-29 Takeda Pharmaceuticals Co Protéines de fusion d'uti
US12404526B2 (en) * 2017-06-07 2025-09-02 Spark Therapeutics, Inc. Enhancing agents for improved cell transfection and/or rAAV vector production
WO2020106881A1 (fr) * 2018-11-20 2020-05-28 Diamedica Inc. Polypeptides d'ulinastatine modifiés
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
JP2021080177A (ja) 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途
EP4114428A4 (fr) 2020-03-05 2025-03-12 Diamedica USA Inc. Polypeptides d'ulinastatine
WO2022165031A1 (fr) * 2021-01-29 2022-08-04 DiaMedica USA Inc. Polypeptides d'ulinastatine pour le traitement de maladies

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
EP0401508B1 (fr) 1989-05-13 1994-11-23 Bayer Ag Inhibiteurs de protéinase, leur procédé de préparation ainsi que compositions pharmaceutiques les contenant
JPH0584083A (ja) 1990-11-13 1993-04-06 Mochida Pharmaceut Co Ltd 新規ポリペプチド、それをコードする新規ｄｎａ、新規ポリペプチドの製造方法、新規医薬組成物、および新規酵素阻害方法
JP2769083B2 (ja) 1993-02-22 1998-06-25 日清食品株式会社 エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法
BR9708021A (pt) 1996-03-11 1999-07-27 Bayer Ag Proteína substancialmente purificada composição farmacêutica sequência de ácido nucleico isolada vetor de express o de protéina auto-replicante e processos para inibir a atividade de protéinas de serina tratar uma condição e preparar um medicamento de uma proteína
DE19725014A1 (de) 1997-06-13 1998-12-17 Bayer Ag Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten
ATE515515T1 (de) * 2004-03-30 2011-07-15 Glaxo Group Ltd Immunglobuline gegen menschlisches osm
EP1791866A2 (fr) * 2004-08-11 2007-06-06 Trubion Pharmaceuticals, Inc. Proteines de fusion a domaine de liaison
CA2609262A1 (fr) * 2005-06-03 2006-12-07 Mochida Pharmaceutical Co., Ltd. Proteine fusionnee possedant un anticorps anti-cd14
PL1981519T3 (pl) 2005-12-29 2018-07-31 Dyax Corp. Hamowanie proteaz
HRP20170374T1 (hr) * 2008-09-26 2017-05-05 Ucb Biopharma Sprl Biološki proizvodi
CN102580085B (zh) * 2008-10-13 2013-09-18 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗脓毒症药物中的应用
CN101721699B (zh) * 2008-10-13 2012-11-07 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗伴随vegf升高的炎症反应的药物中的应用
EP2427207B1 (fr) * 2009-05-05 2017-08-16 Amgen, Inc Mutants de fgf21 et leurs utilisations
SI3053932T1 (sl) * 2010-02-19 2021-01-29 Xencor, Inc. Novi CTLA4-IG imunoadhezini
PH12013502441B1 (en) * 2011-04-29 2019-02-08 Univ Washington Therapeutic nuclease compositions and methods
US8619331B2 (en) 2011-07-19 2013-12-31 Xerox Corporation Simulated paper texture using clear toner and glossmark on texture-less stock
US9988611B2 (en) * 2011-12-01 2018-06-05 Ap Biosciences, Inc. Protein inhibitors to complement and VEGF pathways and methods of use thereof
JP5855239B2 (ja) * 2012-04-23 2016-02-09 株式会社Ｎｒｌファーマ ラクトフェリン融合タンパク質及びその製造方法
CN103044554B (zh) * 2012-05-14 2014-08-27 旭华（上海）生物研发中心有限公司 重组二聚化人尿胰蛋白酶抑制剂、其制备方法及其应用
JP2013253079A (ja) * 2012-05-14 2013-12-19 Xuhua (Shanghai) Biological Research & Development Center Co Ltd 生物学的に活性なヒト尿中トリプシンインヒビターのＦｃ融合タンパク質並びにその調製および使用
MA39347B2 (fr) * 2014-02-24 2020-05-29 Takeda Pharmaceuticals Co Protéines de fusion d'uti

Also Published As

Publication number Publication date
CY1120997T1 (el) 2019-12-11
MX2024000004A (es) 2024-02-20
RS58285B1 (sr) 2019-03-29
EA202091567A1 (ru) 2021-07-30
ECSP16076535A (es) 2017-08-31
AU2019204448B2 (en) 2021-06-10
KR102461210B1 (ko) 2022-10-31
MA39347A1 (fr) 2018-06-29
JP2023123763A (ja) 2023-09-05
EP3110434B1 (fr) 2018-09-19
SI3110434T1 (sl) 2019-02-28
IL247321B (en) 2020-06-30
SG11201606691QA (en) 2016-09-29
ES2700149T3 (es) 2019-02-14
NZ760789A (en) 2023-03-31
US20220127334A1 (en) 2022-04-28
BR112016019390B1 (pt) 2023-11-14
EA037256B1 (ru) 2021-02-26
MX2016010950A (es) 2017-04-25
JO3729B1 (ar) 2021-01-31
KR102722304B1 (ko) 2024-10-28
MX2019013124A (es) 2020-08-31
LT3110434T (lt) 2018-12-27
IL247321A0 (en) 2016-09-29
GEAP201814277A (en) 2018-12-25
CN110092837A (zh) 2019-08-06
EP3443978A1 (fr) 2019-02-20
JP2017512058A (ja) 2017-05-18
AU2021225156A1 (en) 2021-09-30
EA201691702A1 (ru) 2017-01-30
PH12016501629B1 (en) 2023-10-20
AR101597A1 (es) 2016-12-28
KR20240155987A (ko) 2024-10-29
TW201630931A (zh) 2016-09-01
MX384070B (es) 2025-03-14
CA2939639A1 (fr) 2015-08-27
TWI694084B (zh) 2020-05-21
AU2021225156B2 (en) 2022-11-24
UA118866C2 (uk) 2019-03-25
NZ724196A (en) 2022-01-28
JP2022002513A (ja) 2022-01-11
PT3110434T (pt) 2018-12-19
CR20160444A (es) 2017-04-21
PE20170257A1 (es) 2017-03-30
SG10201708400QA (en) 2017-11-29
KR20160141718A (ko) 2016-12-09
MY178774A (en) 2020-10-20
EP3110434A1 (fr) 2017-01-04
SMT201800674T1 (it) 2019-01-11
CL2016002136A1 (es) 2017-08-11
HRP20182029T1 (hr) 2019-02-08
BR112016019390A2 (pt) 2017-10-24
US9856310B2 (en) 2018-01-02
JP6574431B2 (ja) 2019-09-11
AU2019204448A1 (en) 2019-07-11
NZ760008A (en) 2023-03-31
AU2015218704A1 (en) 2016-09-22
ZA201606327B (en) 2019-01-30
PL3110434T3 (pl) 2019-01-31
CA3178241A1 (fr) 2015-08-27
CN106232135B (zh) 2019-12-10
US20160362475A1 (en) 2016-12-15
GEP20196970B (en) 2019-04-25
US10351618B2 (en) 2019-07-16
CN106232135A (zh) 2016-12-14
CA2939639C (fr) 2023-01-24
DK3110434T3 (en) 2019-01-14
CN110092837B (zh) 2024-01-02
DOP2016000202A (es) 2016-12-15
US20200040062A1 (en) 2020-02-06
AU2015218704B2 (en) 2019-05-02
AU2023200875A1 (en) 2023-04-27
US20180072795A1 (en) 2018-03-15
KR20220151005A (ko) 2022-11-11
JP6938565B2 (ja) 2021-09-22
JP2019187427A (ja) 2019-10-31
WO2015127391A1 (fr) 2015-08-27
PH12016501629A1 (en) 2017-02-06

Similar Documents

Publication Publication Date Title
MA43018B1 (fr) Anticorps anti-pd1 et procédés d'utilisation
EP3679141C0 (fr) Méthodes et compositions pour inhiber l'expression de la ldha
EA201890493A1 (ru) РЕПРЕССОРЫ Htt И ИХ ПРИМЕНЕНИЕ
MA40938A (fr) Anticorps anti-cd79b et méthodes d'utilisation desdits anticorps
MA39347B2 (fr) Protéines de fusion d'uti
EA202092435A2 (ru) Моноклональные антитела против bcma
MA40682B1 (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
MA40534B1 (fr) Inhibiteurs de mk2 et leurs utilisations
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
MY193728A (en) Muscarinic receptor agonists
CY1119489T1 (el) Υποκατεστημενη πιπεριδυλο-αιθυλο-πυριμιδινη ως αναστολεας της ο-ακυλο τρανσφερασης της γκρελινης
MX389001B (es) Moduladores de interacción de sestrina-gator2 y sus usos.
EA201600122A1 (ru) Новые изоиндолиновые или изохинолиновые соединения, способ их получения и фармацевтические композиции, содержащие их
TW201613934A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
MX377774B (es) Formulaciones de proteinas.
WO2016138538A3 (fr) Utilisation thérapeutique d'anticorps de liaison à l'intégrine
MX369072B (es) Producto para el cuidado bucal y métodos para uso y fabricación de este.
UA117779C2 (uk) Піразини як модулятори gpr6
EA201691493A1 (ru) Замещенные n-арилпиридиноны
MA39230B1 (fr) Hexahydrofuropyrroles utilisés comme inhibiteurs de pde1
PH12016501326A1 (en) (s)-3'-methyl-abscisic acid and esters thereof
EA201692227A1 (ru) Производные сложных аминоэфиров
PH12017501869A1 (en) (s)-2'-vinyl-abscisic acid derivatives
EP3387431A4 (fr) Systèmes, méthodes et compositions pour améliorer la spécificité de l'hybridation des acides nucléiques
EA201691203A1 (ru) Твёрдые формы тенофовира